Increasing interests towards ‘edoxaban’ due to the NOAC benefit enlargement

Along with the news about the benefit enlargement, the industry has paid attention to the domestic acceptance period of the fourth New Oral Anti-Coagulant(NOAC).

According to the industry concerned on the 29^th, Daiichi-Sankyo is expected to work on the approval procedure of the Ministry of Food and Drug Safety for ‘Savaysa(edoxaban)’ targeting at the domestic launch in 2016.

Savaysa has curre...